We have found a target for inhibiting osteoclastogenesis by means of interfering with cell fusion. This target is highly expressed in RA, a disease characterized by detrimental bone loss. In this ConcepTT grant, we will further validate the potential of the anti-Sn therapy in inflammation induced bone loss and will further refine the therapeutic potential by investigating the role of Sn in a TNF independent RA model.